EGFR and neoplasm: In order to circumvent third generation EGFR TKI resistance, screening a library of about 2.5 million compounds, EAI045 was found to overcome T790M and C797S mediated resistance being an allosteric inhibitor of EGFR, promoting tumor shrinkage in combination with cetuximab in mice tumors harboring L858R, T790M and C797S mutations.